HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

现在，吉利德决定将这2款候选疫苗完全掌控在自己手中。根据5月22日提交给美国证券交易委员会的一份文件， 吉利德将为此总共支付1000万美元，其中300万美元将在交易结束时支付，剩余的700万美元将分三阶段支付，对应技术转移计划的推进步骤。

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations. The news was announced in a stock exchange ...

Gilead's in-line product sales, slight EPS beat and lower expenses were "positive," while the key catalyst for the company's shares will be a "clean and smooth approval" in the United States of ...